# GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ)

> **NCT07738341** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Eddingpharm (Zhuhai) Co., Ltd.** · enrollment: 270 (estimated)

## Conditions studied

- Breast Cancer (Locally Advanced or Metastatic)

## Interventions

- **DRUG:** GB268
- **DRUG:** Nab-Paclitaxel
- **DRUG:** Datopotamab Deruxtecan (Dato-DXd)
- **DRUG:** Sacituzumab Tirumotecan

## Key facts

- **NCT ID:** NCT07738341
- **Lead sponsor:** Eddingpharm (Zhuhai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2029-08-01
- **Final completion:** 2030-08-01
- **Target enrollment:** 270 (ESTIMATED)
- **Last updated:** 2026-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07738341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07738341, "GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07738341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*